- Home
- TNXP vs LOKV Comparison
TNXP vs LOKV Comparison
Compare TNXP & LOKV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- LOKV
- Stock Information
- Founded
- TNXP 2007
- LOKV 2024
- Country
- TNXP United States
- LOKV United States
- Employees
- TNXP N/A
- LOKV N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- LOKV
- Sector
- TNXP Health Care
- LOKV
- Exchange
- TNXP Nasdaq
- LOKV Nasdaq
- Market Cap
- TNXP 335.6M
- LOKV 294.3M
- IPO Year
- TNXP N/A
- LOKV 2025
- Fundamental
- Price
- TNXP $26.54
- LOKV $10.18
- Analyst Decision
- TNXP Buy
- LOKV
- Analyst Count
- TNXP 1
- LOKV 0
- Target Price
- TNXP $70.00
- LOKV N/A
- AVG Volume (30 Days)
- TNXP 1.9M
- LOKV 9.7K
- Earning Date
- TNXP 08-11-2025
- LOKV 01-01-0001
- Dividend Yield
- TNXP N/A
- LOKV N/A
- EPS Growth
- TNXP N/A
- LOKV N/A
- EPS
- TNXP N/A
- LOKV N/A
- Revenue
- TNXP $9,831,000.00
- LOKV N/A
- Revenue This Year
- TNXP $21.19
- LOKV N/A
- Revenue Next Year
- TNXP $722.94
- LOKV N/A
- P/E Ratio
- TNXP N/A
- LOKV N/A
- Revenue Growth
- TNXP N/A
- LOKV N/A
- 52 Week Low
- TNXP $6.76
- LOKV $10.00
- 52 Week High
- TNXP $130.00
- LOKV $11.75
- Technical
- Relative Strength Index (RSI)
- TNXP 32.47
- LOKV N/A
- Support Level
- TNXP $34.50
- LOKV N/A
- Resistance Level
- TNXP $29.70
- LOKV N/A
- Average True Range (ATR)
- TNXP 3.35
- LOKV 0.00
- MACD
- TNXP -1.55
- LOKV 0.00
- Stochastic Oscillator
- TNXP 4.29
- LOKV 0.00
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About LOKV Live Oak Acquisition Corp. V Class A Ordinary Shares
Live Oak Acquisition Corp V is a blank check company.